The contemporary landscape of American healthcare is characterised by a paradoxical tension between the exponential growth of medical knowledge and the diminishing temporal capacity of the clinical workforce to synthesize and apply that information. As of early 2026, the doubling time of medical knowledge has plummeted to approximately 73 days, creating a cognitive environment where a physician graduating today will experience several doublings of the global medical knowledge

The European healthcare technology (HealthTech) mergers and acquisitions (M&A) market is navigating a period of cautious yet discernible rebound in 2025. This resurgence is primarily propelled by improving macroeconomic conditions, substantial private equity dry powder and a pervasive strategic imperative for digital transformation across the healthcare ecosystem.

Private equity firms have traditionally focused on investing in large, high-growth healthcare technology companies. However, there is a growing opportunity for private equity firms to tap into the midtier of the healthtech landscape. These midtier companies have demonstrated a proof of concept, have won flagship customers, and are consistently profitable. However, they are unlikely to reach billion-dollar valuations. This makes them attractive targets for private equity fi